Previous reports investigating PI3K pathway inhibition in bladder cancer have demonstrated that cells possessing activating mutations in PIK3CA are selectively sensitive to PI3K or AKT inhibition, while TSC1 or mTOR mutations contribute to sensitivity to rapalogs [40–42]. Here, TSC1 is linked to urinary bladder carcinoma.